Novel Analgesic Breakthrough: Xinhua Pharmaceutical’s Class 1 Drug LXH-2103 Secures Clinical Approval with Medicilon’s Preclinical Support
Shandong Xinhua Pharmaceutical Co., Ltd., the core subsidiary of Shandong Hualu Holdings Co., Ltd., has obtained official clinical trial approval from the National Medical Products Administration (NMPA) for LXH-2103 Injection, its self-developed Class 1 innovative drug. The candidate is approved for clinical research in the treatment of moderate to severe postoperative pain, marking a key […]
Medicilon Empowers IxCell’s IxCell PB-ZRAK Injection to Secure Clinical Trial Approval for Advanced Hepatocellular Carcinoma
Recently, IxCell has obtained implied approval from the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the clinical trial application of its independently developed IxCell PB-ZRAK Injection. The novel cell therapy product is indicated for the treatment of unresectable or metastatic advanced hepatocellular carcinoma (HCC) in patients with disease progression […]
Medicilon Delivers One Stop Preclinical Support as Yizhong Pharma Secures NMPA Clinical Approval for YXC‑001 Tri‑functional Antibody Fusion Protein and YXC‑002 4th‑Generation EGFR Kinase Inhibitor
Yizhong Pharma, a STAR-Market-listed biotech company, has obtained Clinical Trial Approval Notices from the National Medical Products Administration (NMPA) for two proprietary innovative drug candidates: YXC-001, a tri functional antibody fusion protein, and YXC-002, a 4th-generation EGFR kinase inhibitor. As Yizhong Pharma’s CRO partner, Medicilon executed full-scope preclinical studies (PD, PK, Tox) for YXC -001 […]
World’s First Phase III Positive B7-H3 ADC: Medicilon Congratulates MediLink Therapeutics on NDA Acceptance of Icontamrotamab
On July 18, China’s Center for Drug Evaluation (CDE) accepted the New Drug Application (NDA) for icontamrotamab for injection (Tam-Peli, YL201), a B7-H3-targeted ADC independently developed by MediLink Therapeutics. As the world’s first B7-H3 ADC with positive Phase III results, YL201 has officially entered its launch phase, offering a promising new treatment option for patients […]
Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’
The 74th ASMS Annual Conference on Mass Spectrometry and Allied Topics, held in San Diego from 31 May to 4 June 2026, drew thousands of leading experts from across the global mass spectrometry community. Among the ~3,000 posters presented, Bioanalysis Zone – a premier independent media platform in bioanalytical science – selected just fivefor its […]
Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards
Livzon Pharmaceutical has secured NMPA marketing approval for LiYouBao®, its self-developed recombinant human follicle-stimulating hormone injection. The approval marks a key milestone for Livzon’s fertility pipeline, expanding its market-leading urinary FSH (u-FSH) product portfolio to build a dual u-FSH and recombinant FSH (r-FSH) technology platform. As Livzon’s trusted preclinical CRO partner, Medicilon provided integrated pharmacokinetic, […]
Medicilon Boston R&D Center Awarded Full AAALAC International Accreditation, Further Elevating Global Service Capabilities
Recently, Medicilon Boston R&D Center has successfully passed the rigorous review by AAALAC International and achieved full AAALAC International accreditation. Following the first AAALAC accreditation of its Shanghai R&D Center back in 2009, this renewed recognition proves that Medicilon’s Boston facility has met world-class standards in laboratory animal welfare, ethical supervision, quality management and operational […]
AACR 2026 Special Report: An In-Depth Review of Medicilon’s Three Technical Posters | Bilingual
The AACR Annual Meeting convenes leading cancer experts in San Diego, California, from April 17-22, 2026. Medicilon, with over 20 years of preclinical CRO experience, is represented by Dr. Qingcong Lin, Dr. Mingfeng Bai, and Dr. Steven Zhang. The team is presenting three technical posters highlighting Medicilon’s integrated solutions in conjugate drug analysis, autoimmune CAR-T evaluation models, and end-to-end AOC/RNAi drug […]
Medicilon Signs Five-Year Strategic Cooperation Agreement with BioPartners X to Jointly Promote Innovative Drug R&D
On March 31, 2026, Medicilon officially signed a long-term strategic cooperation framework agreement with BioPartners X. Mr. Gong Huimin, Chairman and CEO of BioPartners X, Dr. Liu Tong, Chief Scientist, Mr. Luo Wusong and Mr. Xu Changlu, Vice Presidents of Strategic Investment, and Mr. Li Ao, Non-Clinical Director, together with Dr. Chen Chunlin, Founder and […]
Medicilon and Protheragen Forge Strategic Partnership to Build a Collaborative “Project + Platform” Model
On April 6, Medicilon formally signed a strategic cooperation agreement with Protheragen and its affiliated companies. Leveraging a collaborative “Project + Platform” model, the two parties will integrate Protheragen’s strengths in innovative drug incubation and global project sourcing with Medicilon’s one-stop preclinical pharmaceutical R&D service platform, jointly building an efficient, compliant and internationalized drug R&D […]
